Skip to main content
. 2018 Mar 15;11:42. doi: 10.1186/s13045-018-0585-5

Fig. 2.

Fig. 2

Changes in bone marrow fibrosis grade during ruxolitinib (RUX) therapy and best available therapy (BAT). Individual changes were calculated as a worsening (cases with baseline BM fibrosis grade 3 were excluded from this analysis because further progression is not defined), b improvement, or c improvement or stabilization